Elevated Serum FGG Levels Prognosticate and Promote the Disease Progression in Prostate Cancer.

Peng, H H; Wang, J N; Xiao, L F; Yan, M; Chen, S P; Wang, L; Yang, K

Peng, H H; Wang, J N; Xiao, L F; Yan, M; Chen, S P; Wang, L; Yang, K.

Afiliação

Peng HH; Department of Urology, Chengdu Fifth People's Hospital, Chengdu, China.
Wang JN; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Xiao LF; Department of Reproductive Medicine, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Yan M; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Chen SP; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Wang L; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yang K; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.

Front Genet ; 12: 651647, 2021.

Article em En | MEDLINE | ID: mdl-33995485

Palavras-chave

ELISA; FGG; biomarkers; castration-resistant prostate cancer; cell proliferation; iTRAQ

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Genet Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google